Literature DB >> 15506675

A comprehensive team approach to the management of patients with Prader-Willi syndrome.

Urs Eiholzer1, Barbara Y Whitman.   

Abstract

Prader-Willi syndrome (PWS) is a genetic disorder characterized by extreme obesity accompanied by other, multisystem clinical manifestations encompassing both physical and behavioral/cognitive abnormalities. The multi-dimensional problems of patients with PWS cannot be treated with a single intervention and benefit from a team approach to management to optimize outcomes. Childhood stature below target height and reduced final height are some defining characteristics of PWS, and compelling evidence from growth hormone (GH) treatment trials suggests that hypothalamic GH deficiency exists. Treatment with GH has been shown to increase height velocity in children with PWS, decrease weight-for-height index values and body fat mass, and have a positive effect on lean body mass during at least the first year of therapy. In addition to medical concerns, the behavioral manifestations, including an uncorrectable deficit in appetite control, and cognitive limitations associated with PWS, require long-term multidisciplinary management.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15506675     DOI: 10.1515/jpem.2004.17.9.1153

Source DB:  PubMed          Journal:  J Pediatr Endocrinol Metab        ISSN: 0334-018X            Impact factor:   1.634


  13 in total

1.  Recurrent panniculitis in an adolescent boy with Prader-Willi syndrome.

Authors:  Alexander K C Leung; William Lane M Robson
Journal:  J Natl Med Assoc       Date:  2006-10       Impact factor: 1.798

2.  Growth hormone therapy is safe and effective in patients with lysinuric protein intolerance.

Authors:  Harri Niinikoski; Risto Lapatto; Matti Nuutinen; Laura Tanner; Olli Simell; Kirsti Näntö-Salonen
Journal:  JIMD Rep       Date:  2011-06-22

3.  Mortality in Prader-Willi syndrome.

Authors:  Stewart L Einfeld; Sophie J Kavanagh; Arabella Smith; Elizabeth J Evans; Bruce J Tonge; John Taffe
Journal:  Am J Ment Retard       Date:  2006-05

4.  Growth hormone therapy improves exercise capacity in adult patients with Prader-Willi syndrome.

Authors:  L A Gondoni; L Vismara; P Marzullo; R Vettor; A Liuzzi; G Grugni
Journal:  J Endocrinol Invest       Date:  2008-09       Impact factor: 4.256

Review 5.  Epilepsy in Prader-Willi syndrome: clinical, diagnostic and treatment aspects.

Authors:  Alberto Verrotti; Claudia Soldani; Daniela Laino; Renato d'Alonzo; Salvatore Grosso
Journal:  World J Pediatr       Date:  2014-05-07       Impact factor: 2.764

6.  Scoliosis in patients with Prader Willi Syndrome - comparisons of conservative and surgical treatment.

Authors:  Hans-Rudolf Weiss; Deborah Goodall
Journal:  Scoliosis       Date:  2009-05-06

7.  Obesity and Prader-Willi Syndrome Affect Heart Rate Recovery from Dynamic Resistance Exercise in Youth.

Authors:  Diobel M Castner; Susan J Clark; Daniel A Judelson; Daniela A Rubin
Journal:  Diseases       Date:  2016-01-15

8.  Clinical implications of gait analysis in the rehabilitation of adult patients with "Prader-Willi" Syndrome: a cross-sectional comparative study ("Prader-Willi" Syndrome vs matched obese patients and healthy subjects).

Authors:  Luca Vismara; Marianna Romei; Manuela Galli; Angelo Montesano; Gabriele Baccalaro; Marcello Crivellini; Graziano Grugni
Journal:  J Neuroeng Rehabil       Date:  2007-05-10       Impact factor: 4.262

9.  French database of children and adolescents with Prader-Willi syndrome.

Authors:  Catherine Molinas; Laurent Cazals; Gwenaelle Diene; Melanie Glattard; Catherine Arnaud; Maithe Tauber
Journal:  BMC Med Genet       Date:  2008-10-02       Impact factor: 2.103

10.  Prader-Willi syndrome in neonates: twenty cases and review of the literature in Southern China.

Authors:  Ping Wang; Wei Zhou; Weiming Yuan; Longguang Huang; Ning Zhao; Xiaowen Chen
Journal:  BMC Pediatr       Date:  2016-08-09       Impact factor: 2.125

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.